Is Your Chlorthalidone on the Recall List?

The recall covers about 25,000 bottles of generic chlorthalidone 25 mg sent to pharmacies nationwide, split across two actions from Inventia Healthcare (distributed by Rising Pharma). FDA testing found tablets failed dissolution specifications: some pills may not break apart and release drug at the rate the label requires. Nothing harmful was found in them. Class II means temporary or medically reversible consequences with a remote chance of serious injury. The June 5, 2026 action is D-0610-2026, covering 11,460 bottles; the September 3, 2026 action is D-0852-2026, covering another 13,567. No injuries have been tied to any lot.

The 60-second bottle check

Pull the bottle. The label lists a lot number near the expiration date. Only three combinations are recalled.

All three expire April 2027. If your bottle doesn't match a lot number and that expiration, it isn't part of the recall. If it does, keep taking your dose on schedule and call your pharmacy today to arrange a replacement bottle or an equivalent diuretic chosen by your prescriber.

Why pausing is the wrong fix

The impulse to toss the bottle and wait is understandable. It's also the one response with measurable harm attached. A meta-analysis of 27 million hypertensive patients found that missing doses raises systolic pressure by about 3 to 4 mmHg and more than doubles the odds of uncontrolled blood pressure. In a cohort of 238,950 adults, poor adherence raised the composite risk of death, heart attack, stroke, and heart failure hospitalization at every blood pressure stratum.

The 2018 valsartan recall is the closest analog. Hypertensive patients still exposed to the recalled drug had about a 22% increase in composite cardiac events (heart attacks, heart failure, strokes, severe hypertension) within six months. Population coverage held up only because switching surged: within 90 days of the first recall, switch rates jumped by about 8.5 percentage points, a more than threefold relative increase over baseline. People with better pharmacy access switched faster. The ones who quietly stopped did worst.

The harm you can actually prevent this week isn't swallowing a slightly under-potent pill. It's the pause while you decide what to do.

What a same-week swap looks like

Chlorthalidone is a long-acting diuretic that has anchored first-line blood pressure treatment for decades. In SHEP, low-dose chlorthalidone cut strokes by more than a third in older adults with isolated systolic hypertension. In ALLHAT, the largest comparative hypertension trial ever run, it matched the ACE inhibitor and calcium channel blocker arms on coronary events and beat both at preventing heart failure. Substitutes are available if your pharmacist needs them.

Call the pharmacy that filled your prescription. Ask them to check your refill against the three recalled lots and dispense a replacement from an unaffected lot, or substitute hydrochlorothiazide at an equivalent dose if stock is tight. Keep taking your current dose on schedule in the meantime. Home cuff readings over a few days will show whether your pressure holds through the switch, and you can check your potassium with a basic metabolic panel, the lab worth watching on any thiazide.

What would change this advice

Three things would change the answer. An FDA upgrade to Class I would raise the stakes of staying on a recalled bottle. MedWatch reports of actual injuries tied to RISA24001, RISB24002, or RISA24002 would turn under-dosing into real harm. A chlorthalidone shortage severe enough that neither a replacement nor an equivalent diuretic can be dispensed within a few days would turn the swap into a bridging conversation your prescriber needs to run. None of those is in play. Swap, don't stop.